Nano-X director Alroy reports option, share holdings
Nano-X Imaging Ltd. director Erez Alroy filed an initial ownership report showing direct holdings of the company’s ordinary shares and stock options.
Rhea-AI Filing Summary
Nano-X Imaging Ltd. director Erez Alroy filed an initial ownership report showing direct holdings of the company’s ordinary shares and stock options. He reports 6,962 ordinary shares in one line and 17,544 ordinary shares in another, reflecting different grant types.
Alroy also holds stock options covering 50,000 ordinary shares with a fixed exercise price of $17.63 per share that expire on December 28, 2032, and options over 10,000 ordinary shares at $11.52 per share expiring on December 31, 2033. Footnotes explain that one ordinary-share position consists of restricted share units granted on December 10, 2025, vesting in twelve equal monthly installments over one year, and that the option grants vest in 16 equal quarterly installments over four years from their respective reference dates.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Alroy Erez
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy ordinary shares) — 60,000 contracts (Direct);
Ordinary shares — 24,506 shares (Direct)
Footnotes (3)
- F1. The ordinary shares reported in this row consist of shares underlying restricted share units that were granted to the Reporting Person on December 10, 2025 and that vest in twelve equal monthly installments such that they will be fully vested upon the one-year anniversary of the grant date.
- F2. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the date of appointment of the Reporting Person to the Issuer's Board of Directors on June 30, 2022, such that all options reported in this row will be exercisable on the four-year anniversary of that appointment date (June 30, 2026).
- F3. The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027).
Key Figures
Ordinary shares holding 1: 6,962 shares
Ordinary shares holding 2: 17,544 shares
Stock options grant 2022: 50,000 shares at $17.63
+4 more
7 metrics
Ordinary shares holding 1
6,962 shares
Direct ordinary shares reported as of the Form 3 date
Ordinary shares holding 2
17,544 shares
Additional direct ordinary shares reported as of the Form 3 date
Stock options grant 2022
50,000 shares at $17.63
Options over ordinary shares, expiration December 28, 2032
Stock options grant 2023
10,000 shares at $11.52
Options over ordinary shares, expiration December 31, 2033
RSU vesting period
12 monthly installments
Restricted share units granted December 10, 2025 vest over one year
Option vesting 2022 grant
16 installments of 6.25%
Quarterly vesting from June 30, 2022 to June 30, 2026
Option vesting 2023 grant
16 installments of 6.25%
Three-month anniversaries from August 14, 2023 to August 14, 2027
Key Terms
restricted share units, Stock Option (right to buy ordinary shares), ordinary shares, vest and become exercisable, +1 more
5 terms
vest and become exercisable financial
"vest and become exercisable in 16 equal quarterly installments of 6.25% each"
grant approval date financial
"four-year anniversary of that grant approval date (August 14, 2027)"
FAQ
What does Nano-X Imaging (NNOX) director Erez Alroy report on this Form 3?
He reports his initial ownership of Nano-X Imaging ordinary shares and stock options as a company director. The filing lists two direct ordinary-share positions and two option grants over additional ordinary shares, along with detailed vesting schedules and option expiration dates.
What is the vesting schedule for Erez Alroy’s 2022 Nano-X Imaging option grant?
Options granted December 28, 2022 vest in 16 equal quarterly installments of 6.25% each, starting from June 30, 2022, his Board appointment date. All options from this grant become fully exercisable on the four-year anniversary of that appointment, June 30, 2026.
What is the vesting schedule for Erez Alroy’s 2023 Nano-X Imaging option grant?
Options granted December 31, 2023 vest in 16 equal installments of 6.25% each on every three-month anniversary of August 14, 2023, the Board approval date. All options from this grant become exercisable on the four-year anniversary of that approval date, August 14, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
